Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).

Roberta Sanfilippo,Richard L Hayward,Jammbe Musoro,Charlotte Benson,Michael Gordon Leahy,Antonella Brunello,Jean-Yves Blay,Neeltje Steeghs,Ingrid M E Desar,Nasim Ali,Alice Hervieu,Khin Thway,Sandrine Marreaud,Saskia Litiere,Bernd Kasper

JAMA oncology（2022）

引用 3|浏览30

暂无评分

摘要

This nonrandomized phase 2 clinical trial met its primary end point, with 21 of 38 patients (55%) being progression free at 12 weeks. These results suggest important activity of cabazitaxel in patients with metastatic or inoperable locally advanced DDLPS. The drug is worth being further studied in these tumors in a phase 3 setting.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要